symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
CLCS,0.45,-141.10197,5290,17188020,0,3.0E-4-1.5,-0.28,"Cell Source, Inc.",USD,0001569340,US15114L1044,15114L104,Other OTC,PNK,Biotechnology,https://www.cell-source.com,"Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.",Mr. Itamar  Shimrat,Healthcare,US,1,646 416 7896,57 West 57th Street,New York,NY,10019,,1.00817,https://financialmodelingprep.com/image-stock/CLCS.png,2014-05-01,False,False,True,False,False
